{
    "nct_id": "NCT03090737",
    "official_title": "An Open-label, Single-arm Phase II Safety Study of Nivolumab in Participants With Advanced or Metastatic Non-small Cell Lung Cancer Who Have Progressed During or After Receiving at Least One Prior Systemic Regimen (CheckMate 907: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 907)",
    "inclusion_criteria": "* Non small cell lung cancer (Squamous or non-squamous)\n* At least one prior anti-cancer therapy that did not work\n* ECOG Performance Scale 0-1\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Cancer that has spread to the brain or leptomeninges unless there is no evidence of progression by MRI for 8 weeks after treatment is complete and within 28 days before first dose of study drug\n* Active, known or suspected autoimmune disease or infection\n* Prior immuno-oncology therapy\n* Corticosteroids within 2 weeks of study drug administration\n\nOther protocol defined inclusion/exclusion criteria could apply",
    "miscellaneous_criteria": ""
}